Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,737 shares of the medical instruments supplier’s stock after selling 55 shares during the period. Raleigh Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $394,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company in the third quarter worth about $33,000. Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC grew its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $46,000. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares in the company, valued at approximately $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,844 shares of company stock worth $2,210,716. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $238.05 on Thursday. The firm’s 50-day simple moving average is $227.44 and its 200 day simple moving average is $232.83. The stock has a market cap of $69.04 billion, a P/E ratio of 40.08, a P/E/G ratio of 1.74 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.42 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.42 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.75%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.